Matt Miksic analyst BARCLAYS

Currently out of the existing stock ratings of Matt Miksic, 342 are a BUY (76.85%), 74 are a HOLD (16.63%), 29 are a SELL (6.52%).

Matt Miksic

Work Performance Price Targets & Ratings Chart

Analyst Matt Miksic, currently employed at BARCLAYS, carries an average stock price target met ratio of 48.43% that have a potential upside of 18.23% achieved within 264 days. Previously, Matt Miksic worked at CREDIT SUISSE, PIPER SANDLER, UBS.

Matt Miksic’s has documented 891 price targets and ratings displayed on 35 stocks. The coverage is on Healthcare, Communication Services sectors.

Most recent stock forecast was given on BSX, Boston Scientific Corp at 28-May-2026.

Wall Street Analyst Matt Miksic

Analyst best performing recommendations are on ORGO (ORGANOGENESIS HOLDINGS).
The best stock recommendation documented was for ISRG (INTUITIVE SURGICAL) at 10/17/2022. The price target of $235 was fulfilled within 8 days with a profit of $44.88 (23.61%) receiving and performance score of 29.51.

Average potential price target upside

ABT Abbott Laboratories ALC Alcon AG BAX Baxter International BSX Boston Scientific Corp EW Edwards Lifesciences Corp GMED Globus Medical HSIC Henry Schein IART Integra LifeSciences Holdings JNJ Johnson & Johnson MDT Medtronic PLC NUVA NuVasive ORGO Organogenesis Holdings SHC Sotera Health Co SYK Stryker WMGI Wright Medical Group N.V XRAY Dentsply Sirona ZBH Zimmer Biomet Holdings ALGN Align Technology DXCM DexCom PODD Insulet TNDM Tandem Diabetes Care ISRG Intuitive Surgical INMD InMode Ltd ZIMV ZimVie BLCO Bausch + Lomb Corp LIVN LivaNova PLC PDCO Patterson Companies SDC SmileDirectClub ATEC Alphatec Holdings BDX Becton Dickinson and Company COO The Cooper Companies Common Stock GEHC GE HealthCare Technologies OBIO Orchestra BioMed Holdings WMG Warner Music Group ZIM ZIM Integrated Shipping Services Ltd

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 19-Sep-2024

$115

$20.88 (22.18%)

$115

16 days ago
(22-Jun-2026)

2/7 (28.57%)

$27.17 (30.93%)

143

Buy Since 02-Jun-2021

$131

$36.88 (39.18%)

$131

2 months 11 days ago
(27-Apr-2026)

9/21 (42.86%)

$38.2 (41.16%)

559

Buy Since 17-Dec-2018

$143

$48.88 (51.93%)

$144

2 months 18 days ago
(20-Apr-2026)

19/31 (61.29%)

$47 (48.96%)

495

Buy Since 18-Jul-2018

$120

$25.88 (27.50%)

$134

2 months 21 days ago
(17-Apr-2026)

10/18 (55.56%)

$23.19 (23.95%)

290

Buy Since 25-May-2021

$120

$25.88 (27.50%)

$150

2 months 21 days ago
(17-Apr-2026)

1/7 (14.29%)

$23.19 (23.95%)

194

Show more analysts

Please expand the browser size to see the chart

Which stock is Matt Miksic is most bullish on?

Potential upside of $224.99 has been obtained for ISRG (INTUITIVE SURGICAL)

Which stock is Matt Miksic is most reserved on?

Potential downside of -$8.04 has been obtained for JNJ (JOHNSON & JOHNSON)

What Year was the first public recommendation made by Matt Miksic?

On 2008

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?